Nature communications · 2026
Three-site cycloadditions within one reaction intermediate with site-selectivity controlled by electronic and size bias.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maitra Chandrima, Barik Debashis, Wu Ting-You, Yang Chia-Jung, Cheng Mu-Jeng, Goddard William A, Liu Rai-Shung
Аннотация
In homogeneous catalysis, a reaction intermediate typically possesses only one reactive site to ensure chemoselectivity. However, such a design limits efficiency and requires multiple independent steps to achieve divergent synthesis. What if a single intermediate could act as a "master key" featuring multiple, differentiated sites that each respond selectively to distinct partners? This concept has remained largely unexplored due to the long-standing challenge of controlling site selectivity. Here, we report the design of a remarkable three-site intermediate (Int-1) that serves as a selective, programmable hub for complex molecular synthesis. Using a gold catalyst and 1,6-allenynes, we generate an intermediate containing three sterically and electronically distinct cycloaddition sites (A, B, and C). The power of this intermediate lies in its intelligent site recognition: site-A reacts exclusively with bulky dipolarophiles, site-B selectively traps nucleophilic partners, and site-C engages electrophilic aldehydes. This precise multi-site control, rationalized by DFT calculations, enables three divergent cycloaddition pathways to proceed from a common intermediate. The discovery of three-site intermediate Int-1 establishes a new paradigm for multi-site divergent synthesis, providing a one-step platform for the efficient generation of structurally diverse benzoxepines-the core scaffolds of numerous bioactive molecules and pharmaceuticals.